Suppr超能文献

包含钠、年龄和性别的终末期肝病模型是接受体外膜肺氧合治疗的COVID-19患者生存的有力预测指标。

Model for End-Stage Liver Disease Including Na, Age, and Sex Is Powerful Predictor of Survival in COVID-19 Patients on Extracorporeal Membrane Oxygenation.

作者信息

Jenkins Freya Sophie, Morjan Mohammed, Minol Jan-Philipp, Yilmaz Esma, Dalyanoglu Ismail, Immohr Moritz Benjamin, Korbmacher Bernhard, Boeken Udo, Lichtenberg Artur, Dalyanoglu Hannan

机构信息

Department of Cardiac Surgery, University of Dusseldorf, 40225 Dusseldorf, Germany.

Medical Faculty, Semmelweis University, 1085 Budapest, Hungary.

出版信息

Diagnostics (Basel). 2024 Sep 4;14(17):1954. doi: 10.3390/diagnostics14171954.

Abstract

AIM

Extracorporeal membrane oxygenation (ECMO) is resource-intensive, is associated with significant morbidity and mortality, and requires careful patient selection. This study examined whether the model for end-stage liver disease (MELD) score is a suitable predictor of in-hospital mortality in patients with COVID-19.

MATERIALS AND METHODS

We retrospectively assessed patients with COVID-19 on ECMO at our institution from March 2020 to May 2021. MELD scoring was performed using laboratory values recorded prior to ECMO initiation. A multiple logistic regression model was established.

RESULTS

A total of 66 patients with COVID-19 on ECMO were included (median age of 58.5 years; 83.3% male). The in-hospital mortality was 74.2%. In relation to mortality, patients with MELD Na scores >13.8 showed 6.5-fold higher odds, patients aged >53.5 years showed 18.4-fold higher odds, and male patients showed 15.9-fold higher odds. The predictive power of a model combining the MELD Na with age and sex was significant (AUC = 0.883, < 0.001). The findings in the COVID-19 patients were not generalizable to a group of non-COVID-19 patients on ECMO.

CONCLUSIONS

A model combining the MELD Na, age, and sex has high predictive power for in-hospital mortality in patients with COVID-19 on ECMO, and it may be clinically useful for guiding patient selection in critically ill COVID-19 patients both now and in the future, should the virus widely re-emerge.

摘要

目的

体外膜肺氧合(ECMO)资源消耗大,与显著的发病率和死亡率相关,且需要仔细选择患者。本研究探讨终末期肝病模型(MELD)评分是否是新型冠状病毒肺炎(COVID-19)患者院内死亡率的合适预测指标。

材料与方法

我们回顾性评估了2020年3月至2021年5月在我院接受ECMO治疗的COVID-19患者。使用启动ECMO前记录的实验室值进行MELD评分。建立多元逻辑回归模型。

结果

共纳入66例接受ECMO治疗的COVID-19患者(中位年龄58.5岁;83.3%为男性)。院内死亡率为74.2%。关于死亡率,MELD Na评分>13.8的患者的比值高6.5倍,年龄>53.5岁的患者的比值高18.4倍,男性患者的比值高15.9倍。将MELD Na与年龄和性别相结合的模型的预测能力显著(曲线下面积[AUC]=0.883,P<0.001)。COVID-19患者的研究结果不能推广到一组接受ECMO治疗的非COVID-19患者。

结论

将MELD Na、年龄和性别相结合的模型对接受ECMO治疗的COVID-19患者的院内死亡率具有较高的预测能力,并且在现在以及未来如果该病毒广泛再次出现时,对于指导重症COVID-19患者的患者选择可能具有临床实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e263/11393913/e44bbe8642fa/diagnostics-14-01954-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验